Miyuki Shimoji Selected Research

Doxorubicin (Adriamycin)

10/2011

Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Miyuki Shimoji Research Topics

Disease

3	Neoplasms (Cancer) 12/2022 - 10/2011
3	Prion Diseases (Transmissible Spongiform Encephalopathies) 10/2011 - 08/2010
1	Hypothermia 05/2023
1	Hyperthermia 05/2023
1	Brain Diseases (Brain Disorder) 10/2011
1	Infections 01/2011

Drug/Important Bio-Agent (IBA)

3	Prion ProteinsIBA 10/2011 - 08/2010
2	Protein Isoforms (Isoforms)IBA 10/2011 - 01/2011
1	Cytochrome P-450 CYP3AIBA 05/2023
1	human ERBB2 proteinIBA 12/2022
1	Immune Checkpoint InhibitorsIBA 12/2022
1	AntibodiesIBA 12/2022
1	AntigensIBA 12/2022
1	Cytostatic AgentsIBA 10/2011
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2011
1	Glutathione Transferase (Glutathione S-Transferase)IBA 10/2011
1	Cisplatin (Platino)FDA LinkGeneric 10/2011
1	Proteins (Proteins, Gene)FDA Link 01/2011
1	PrionsIBA 01/2011
1	Valine (L-Valine)FDA Link 08/2010
1	Codon (Codons)IBA 08/2010
1	Peptide Hydrolases (Proteases)FDA Link 08/2010

Therapy/Procedure

1	Aftercare (After-Treatment) 12/2022
1	Immunotherapy 12/2022
1	Radiotherapy 12/2022
1	Gastrectomy 01/2022
1	Laparotomy 01/2022